OncoOne has been awarded a basic program grant from the FFG for our pioneering work on developing various drug modalities aimed at targeting oxidized macrophage migration inhibitory factor (oxMIF), a novel and promising drug target for solid tumor cancer indications. This grant is designed to

OncoOne opened our labs at the University of Natural Resources and Life Sciences, Vienna.

OncoOne has received a Pre-Seed funding from AWS under the aws PreSeed – Innovative Solutions program. This program supports projects across all sectors that present an innovative startup idea capable of generating positive societal impact and high market potential through scalable business models. The funding

OncoOne has been selected for Accent’s accelerator program, offering a holistic approach to nurture its growth. The program provides in-depth business development guidance, leveraging the Accent team’s expertise and dedication. It includes crafting a tailored Intellectual Property (IP) strategy in collaboration with tecnet tt experts,

OncoOne, founded by Randolf Kerschbaumer, PhD, Michael Thiele, PhD, and Alexander Schinagl, PhD, will advance various drug modalities aimed at targeting oxidized macrophage migration inhibitory factor (oxMIF), an isoform of macrophage migration inhibitory factor (MIF) recognized as a promising novel drug target for solid tumor